CompletedPhase 1NCT00375726

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults

Studying Dengue fever

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Principal Investigator
Anna Durbin, MD, MD
Center for Immunization Research, Johns Hopkins School of Public Health
Intervention
rDEN3/4delta30(ME)(biological)
Enrollment
58 enrolled
Eligibility
18-50 years · All sexes
Timeline
20062008

Study locations (1)

Collaborators

Johns Hopkins Bloomberg School of Public Health

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00375726 on ClinicalTrials.gov

Other trials for Dengue fever

Additional recruiting or active studies for the same condition.

See all trials for Dengue fever

← Back to all trials